Prochownik Edward V
Section of Hematology/Oncology, Children's Hospital of Pittsburgh, Rangos Research Center, Room 2100, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA.
Expert Rev Anticancer Ther. 2004 Apr;4(2):289-302. doi: 10.1586/14737140.4.2.289.
c-Myc is frequently deregulated in human cancers. The c-Myc oncoprotein is a transcription factor, with many of its target genes encoding proteins that initiate and maintain the transformed state. c-Myc is also part of a dynamic network whose members interact selectively with one another and with various transcriptional coregulators and histone-modifying enzymes. This knowledge highlights several points that might be amenable to attack. This review summarizes progress in controlling the extent of c-Myc transcription, translation, interaction with other myc network members, DNA binding and transcriptional activation. Inhibition of c-Myc can be achieved with many of these approaches; however, clinical efficacy will likely require intervention at several levels, perhaps in combination with traditional chemotherapeutic drugs or agents that target other oncoproteins.
c-Myc在人类癌症中经常失调。c-Myc癌蛋白是一种转录因子，其许多靶基因编码启动和维持转化状态的蛋白质。c-Myc也是一个动态网络的一部分，该网络的成员彼此之间以及与各种转录共调节因子和组蛋白修饰酶选择性地相互作用。这些知识突出了几个可能易于攻克的要点。本综述总结了在控制c-Myc转录、翻译、与其他myc网络成员的相互作用、DNA结合和转录激活程度方面的进展。通过许多这些方法都可以实现对c-Myc的抑制；然而，临床疗效可能需要在多个层面进行干预，或许还需要与传统化疗药物或靶向其他癌蛋白的药物联合使用。
